If you spent more time reading literature instead of posting onto social media, you would probably start making more sense.
The ALPHA3 is a registrational trial. Therefore, Cema-cel are well ahead of you. Before the acquisition of Azer-cel by IMU, Cema-cel received a Regenerative Medicine Advanced Therapy (RMAT) designation which can lead to accelerated approval.
Cema-cel is not targeting patients who have failed other treatments. They are specifically targeting front-line (1L) as a consolidation cycle for anyone at high risk of relapse. They are trying to take over as much of the autologous CAR T market without even having to compete with them.
Azer-cel program was delayed because IMU are yet to dose enough patients to confirm an adjusted dosing regimen will not kill the patients. That risk still exists to this day, and it would be foolish not to consider it a factor. IMU management have never publicly disclosed why the dose had to be adjusted despite purchasing Azer-cel with over 80 people treated in phase 1 testing.
IMU management told you Azer-cel has the potential to start a registrational study in 2024 and become the first approved allogeneic CAR T cell therapy for cancer. The FDA never said this.
Nov 10 2023
Sep 2 2024
Over two decades, the Boston Research Group proved that being first to market is the most important factor for market capture. Cema-cel are poised to take that spot.
Show me specifically where LC stated Azer-cel would combine with CF33 for 90% of the solid tumor market.
(20min delay)